Clinical Trials on Skin Melanoma in South Africa

Total 3397 results

Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma

Recurrent Melanoma

United States
AstraZeneca

Completed

Study of CP-675,206 in Refractory Melanoma

Refractory Melanoma

United States, Spain, Canada, France, Italy, United Kingdom, Argentina, Australia, Germany
Pfizer

Active, not recruiting

Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma (COLUMBUS)

Melanoma

Canada, United States, Spain, Germany, Korea, Republic of, Australia, Czechia, Netherlands, France, Hungary, United Kingdom, Switzerland, Singapore, Russian Federation, Italy, Japan, Israel, Brazil, Portugal, Mexico, Greece, Argen... and more
Bristol-Myers Squibb

Completed

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma (IMAGE)

Advanced Cutaneous Melanoma

Germany, Poland, Spain, Australia, France, Argentina, Ireland, Israel, Belgium, United States, Switzerland, United Kingdom, Greece, Austria, Canada
National Cancer Institute (NCI)

Completed

Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma

United States
Bristol-Myers Squibb

Active, not recruiting

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

Unresectable or Metastatic Melanoma

United States, France, Poland, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, Germany, Ireland, Israel, Italy, Netherlands, New Zealand, Norway, Spain, Sweden, Switzerland, United Kingdom, Russian Federation
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)

Malignant Melanoma

United States, Australia, Austria, Brazil, Canada, Chile, China, France, Germany, Israel, Italy, Korea, Republic of, Poland, South Africa, Spain, Sweden, Switzerland, United Kingdom
Ascentage Pharma Group Inc.
Merck Sharp & Dohme LLC

Recruiting

A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Melanoma | P53 Mutation | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Malignant Peripheral Nerve Sheath Tumors | MPNST | Unresectable or Metastatic Melanoma or Advanced Solid Tumors | MDM2 Gene Mutation

United States, Australia
University of Stellenbosch
Stanford University

Completed

Transcutaneous Screening for Risk of Severe Hyperbilirubinemia in South African Newborns

Hyperbilirubinemia | Neonatal Jaundice

South Africa
Celgene
University of Arizona

Completed

A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma

Malignant Melanoma

Canada, United States, Australia, United Kingdom, France, Italy, Spain, Germany, Netherlands
Hoffmann-La Roche

Active, not recruiting

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

Melanoma

United States, Korea, Republic of, United Kingdom, Australia, France, Belgium, Italy, Portugal, Spain, Brazil, Canada, Russian Federation, Germany, New Zealand, Israel, Poland, Greece, Austria, Hungary, Netherlands
Novartis Pharmaceuticals

Completed

Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes (COMBI-APlus)

Malignant Melanoma

Canada, Italy, Czechia, Australia, France, Greece, Israel, Russian Federation, Sweden, United Kingdom, Hungary, Slovakia, Slovenia, Japan, Turkey, Argentina, Finland, Norway, Brazil, Latvia, Lithuania, Poland, Portugal
Hoffmann-La Roche

Completed

A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma (coBRIM)

Malignant Melanoma

United States, Spain, Hungary, Israel, United Kingdom, Australia, Austria, Belgium, Czechia, France, Germany, Italy, Netherlands, Russian Federation, Sweden, Switzerland, Canada, New Zealand, Norway
French National Agency for Research on AIDS and...

Terminated

Effect of Male Circumcision on HIV Incidence (ANRS 1265)

HIV Infections | Herpes Genitalis | Venereal Diseases

South Africa
Novartis Pharmaceuticals

Active, not recruiting

A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma (COMBI-i)

Melanoma

Italy, Czechia, Germany, Hungary, Canada, United States, Argentina, Australia, Austria, France, Israel, Russian Federation, Spain, Sweden, United Kingdom, Thailand, Belgium, Brazil, Greece, Switzerland, Mexico, Netherlands, Denmark, C... and more
Zimmer Biomet

Terminated

A Multicentre Trial to Compare Two Articulating Bearing Surfaces as Used in Cementless Primary Hip Arthroplasty (MagnumCRCT)

Osteoarthritis

Bosnia and Herzegovina, South Africa
Ludwig Institute for Cancer Research
Institute of Cancer Research, United Kingdom

Completed

Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma

Melanoma

United Kingdom, Australia, New Zealand
BioVex Limited
Amgen

Completed

Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

Melanoma

United States, United Kingdom, Canada, South Africa
Amgen
Merck Sharp & Dohme LLC

Terminated

Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma (MASTERKEY-265)

Melanoma

United States, Finland, France, Germany, Italy, Canada, Czechia, Poland, Switzerland, Korea, Republic of, Russian Federation, United Kingdom, Australia, Netherlands, Spain, Austria, Belgium, Hungary, Portugal, Greece, South Africa
GlaxoSmithKline

Completed

Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor

Cancer

Australia, United States
Cleveland Chiropractic College
Durban University of Technology; Murdoch University

Completed

Comparing Manipulation, Rehabilitation and Combination of the Two in the Treatment of Knee Osteoarthritis

Osteoarthritis, Knee

United States, South Africa
Attenuon

Unknown

Randomized Trial of ATN-224 and Temozolomide in Advanced Melanoma

Melanoma

United States
PDL BioPharma, Inc.

Completed

Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy

Melanoma | Metastases

United States
Cancer Insight, LLC
Elios Therapeutics, LLC

Completed

Phase IIB TL + YCWP + DC in Melanoma

Melanoma

United States
DS Biopharma

Completed

Safety and Efficacy Study of Topically Applied DS107 Cream in Mild to Moderate Atopic Dermatitis Patients (AD)

Atopic Dermatitis

United States, Canada, South Africa
Medical University of South Carolina

Withdrawn

Spironolactone for the Treatment of Melasma

Melasma

United States
Bristol-Myers Squibb

Completed

MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

Melanoma | Metastases

United States, Canada, Netherlands, United Kingdom, Germany, Chile, Belgium, France, South Africa, Argentina, Brazil, Hungary, Switzerland
Bayer
Amgen

Completed

Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

Melanoma | Cancer

United States
Bristol-Myers Squibb
Medarex

Completed

Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma

Melanoma

United States, Brazil, France, Italy, South Africa, United Kingdom, Argentina, Australia, Canada, Ireland, Israel, Russian Federation, Spain, Belgium, Germany, Portugal, Chile, Austria, Poland, Netherlands, Ukraine, Czech Republic, ... and more
Bristol-Myers Squibb

Completed

A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma

Melanoma

Italy, France, Spain, Australia
Red Cross War Memorial Childrens Hospital

Unknown

Efficacy of Combining Topical Antibiotic/Steroid/Moisturizer Therapy Compared to Active Comparator in Atopic Dermatitis.

Severe Atopic Dermatitis

South Africa
GlaxoSmithKline

Completed

Parkinson's Disease Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole

Parkinson Disease

Germany, South Africa
AstraZeneca

Completed

CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy

Melanoma

United States, Italy, Spain, Sweden, Belgium, Canada, Poland, Switzerland, France, Russian Federation, United Kingdom, Australia, Argentina, Germany, Netherlands, Israel, South Africa, Austria, Greece, Mexico, Slovakia
New York State Psychiatric Institute
University of Colorado, Denver; National Institute of Allergy and Infectious... and other collaborators

Completed

Use of Antiretroviral (ARV) Drug Levels in Dried Blood Spots (DBS) to Assess and Manage ART Adherence in South Africa (ADD-ART)

Therapeutic Adherence and Compliance

United States, South Africa
Genzyme, a Sanofi Company

Completed

Study of ILX651 in Patients With Inoperable Locally Advanced or Metastatic Melanoma

Melanoma

United States
National Cancer Institute (NCI)
Exelisis

Completed

Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery

Stage IV Uveal Melanoma AJCC v7 | Recurrent Uveal Melanoma | Stage III Uveal Melanoma AJCC v7 | Stage IIIA Uveal Melanoma AJCC v7 | Stage IIIB Uveal Melanoma AJCC v7 | Stage IIIC Uveal Melanoma AJCC v7

United States, Canada
Sapience Therapeutics

Recruiting

A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors

Hepatocellular Carcinoma | Pancreatic Cancer | Ovarian Cancer | Cholangiocarcinoma | Triple Negative Breast Cancer | Metastatic Melanoma | Colon Cancer | Synovial Sarcoma | Breast Cancer Metastatic | Metastatic Colon Cancer | Melanoma Stage IV | Melanoma Recurrent | TNBC - Triple-Negative Breast Cancer | NSCLC, Metastatic and other conditions

United States
GlaxoSmithKline

Completed

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

Melanoma

United States, Italy, United Kingdom, France, Sweden, Germany, Poland, Australia, Belgium, Austria, Canada, Czechia, Greece, Russian Federation, Ukraine, Norway, Switzerland, New Zealand, Argentina
Jennerex Biotherapeutics

Completed

A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma

Melanoma

United States
GlaxoSmithKline

Terminated

Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites

Melanoma and Brain Metastases

United States, Australia
Sanofi Pasteur, a Sanofi Company

Terminated

Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma

Melanoma | Cancer

Canada, United States
Incyte Corporation
Merck Sharp & Dohme LLC

Completed

A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)

Melanoma

United States, France, Italy, United Kingdom, Spain, Belgium, Israel, Mexico, Japan, Canada, Netherlands, Sweden, Korea, Republic of, Australia, Russian Federation, Chile, Germany, Poland, Ireland, New Zealand, Denmark, Switzerland, South Africa
Bristol-Myers Squibb

Active, not recruiting

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

Melanoma | Cancer

United States, Poland, Italy, Belgium, France, Australia, Canada, Germany, Spain, Sweden, Switzerland, United Kingdom
Novartis Pharmaceuticals

Completed

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation (TEAM)

Melanoma

United States, Belgium, Germany, Singapore, Italy, Australia, Netherlands, Sweden, Spain, Canada, Switzerland, Argentina, Brazil, China
Pierre Fabre Medicament
European Organisation for Research and Treatment of Cancer - EORTC

Active, not recruiting

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. (COLUMBUS-AD)

Melanoma

Spain, Canada, Hungary, Italy, Belgium, Netherlands, Australia, Czechia, Greece, Brazil, Portugal, Serbia, Sweden, Norway, Germany, Argentina, Romania, Poland, United Kingdom, Austria, Switzerland, France, South Africa
Bristol-Myers Squibb

Completed

Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma (CheckMate 066)

Melanoma

Canada, Australia, Germany, Italy, Poland, France, Denmark, Argentina, Chile, Spain, Norway, Israel, Sweden, Mexico, Greece, Finland
GlaxoSmithKline

Completed

A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma

Melanoma

Australia, France, Germany, United States, Italy
Genentech, Inc.

Active, not recruiting

A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.

Melanoma

United States, Germany, Australia, Korea, Republic of, Canada, Norway
Viralytics

Completed

Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04) (PSX-X04)

Melanoma | Breast Cancer | Prostate Cancer

Australia
Immune Design
Merck Sharp & Dohme LLC

Completed

Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1

Melanoma - Currently Enrolling | Non-small Cell Lung Cancer - Enrollment Completed | Sarcoma - Enrollment Completed

United States

Clinical Trials on Skin Melanoma in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations